Uveitis Clinical Trial
Official title:
The Treatment of Uveitic Cystoid Macular Edema With Topical Interferon Gamma
Verified date | June 24, 2010 |
Source | National Institutes of Health Clinical Center (CC) |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Background:
- Uveitis is a serious inflammatory condition that affects the eye and can cause vision
loss. A common secondary problem associated with uveitis is macular edema (swelling).
The macula is the part of the eye that is important for central vision, and swelling of
the macula can lead to further vision loss. This condition is usually treated by
medicines that target the immune system, but these medicines sometimes do not work or
may cause side effects.
- Interferon gamma-1b (Actimmune(Registered Trademark)) is a bioengineered protein that
can alter the way inflammatory cells work in the immune system. Interferon gamma-1b is
given as an intramuscular injection; however, this study will use the drug as an eye
drop. This study represents the first time that interferon gamma-1b is given as an eye
drop. Researchers hope that interferon gamma-1b will treat macular edema by decreasing
the swelling in the back of the eye.
Objectives:
- To investigate the safety and effectiveness of treating uveitis-associated macular edema
with interferon gamma-1b.
Eligibility:
- Individuals 18 years of age and older who have been diagnosed with macular edema associated
with uveitis (in one or both eyes) for at least 3 months.
Design:
- Participants will have three planned clinic visits during this study over the course of
2 weeks.
- All participants will have a medical history and eye examination.
- When receiving the drops, participants will have optical coherence tomography (a
detailed scan of the retina) 60 minutes and 30 minutes before the drops; upon receiving
the drops; and 30, 60, and 120 minutes after receiving the drops.
- After receiving the drops, participants will have another eye examination, blood drawn
for samples, and further scans.
- Participants will be asked to return to the NIH Clinical Center 1 week after receiving
the drops for an evaluation....
Status | Completed |
Enrollment | 5 |
Est. completion date | June 24, 2010 |
Est. primary completion date | June 24, 2010 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
- INCLUSION CRITERIA: 1. Participant must be 18 years of age or older. 2. Participant must understand and sign the protocol's informed consent document. 3. Participant has a diagnosis of intermediate, panuveitis or posterior uveitis at least three months prior to study enrollment and has associated CME secondary to uveitis in at least one eye (the study eye). 4. Participant has a central macular thickness greater than or equal to 250 microns in the study eye. 5. Participant is willing to comply with the study procedures and is expected to be able to return for all study visits. 6. Participant has visual acuity of 20/200 or better in the study eye. 7. Female participants of childbearing potential must not be pregnant or breast-feeding. 8. Both female participants of childbearing potential and male participants able to father a child must agree to practice an adequate contraception during the study and for six weeks following the administration of study medication. Acceptable methods of contraception include hormonal contraception (i.e. birth control pills, injected hormones dermal patch or vaginal ring), intrauterine device, barrier methods with spermicide (diaphragm with spermicide, condom with spermicide) or surgical sterilization (hysterectomy, tubal ligation or vasectomy). EXCLUSION CRITERIA: 1. Participant is expected to be unable to tolerate the ocular instillation. 2. Participant is unable to undergo OCT testing. 3. Participant had herpes keratitis in the past. 4. Participant is diagnosed with multiple sclerosis. 5. Participant has a significant active infection (an infection requiring treatment as determined by the medical team) or a history of chronic or recurrent infections that in the principal investigator's best medical judgment would preclude participation. |
Country | Name | City | State |
---|---|---|---|
United States | National Institutes of Health Clinical Center, 9000 Rockville Pike | Bethesda | Maryland |
Lead Sponsor | Collaborator |
---|---|
National Eye Institute (NEI) |
United States,
Andrews HE, Nichols PP, Bates D, Turnbull DM. Mitochondrial dysfunction plays a key role in progressive axonal loss in Multiple Sclerosis. Med Hypotheses. 2005;64(4):669-77. — View Citation
Artuch R, Aracil A, Mas A, Colomé C, Rissech M, Monrós E, Pineda M. Friedreich's ataxia: idebenone treatment in early stage patients. Neuropediatrics. 2002 Aug;33(4):190-3. — View Citation
Artuch R, Aracil A, Mas A, Monrós E, Vilaseca MA, Pineda M. Cerebrospinal fluid concentrations of idebenone in Friedreich ataxia patients. Neuropediatrics. 2004 Apr;35(2):95-8. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | The primary outcome is the change in central macular thickness as measured by OCT as compared with baseline. | |||
Secondary | Secondary outcomes include: changes in macular volume as measured by OCT, changes in visual acuity, changes in intraocular pressure and changes in intraocular inflammation. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04101604 -
Biomarkers of Common Eye Diseases
|
||
Active, not recruiting |
NCT04704609 -
Imaging Quantification of Inflammation (IQI)
|
||
Completed |
NCT03173144 -
Chronic Inflammatory Disease, Lifestyle and Treatment Response
|
||
Withdrawn |
NCT01280669 -
Intravitreal Sirolimus as Therapeutic Approach to Uveitis
|
Phase 2 | |
Terminated |
NCT02907814 -
Measurement of Anterior Chamber Cell Grading Using Ocular Coherence Tomography
|
N/A | |
Active, not recruiting |
NCT02252328 -
Use of Simvastatin as a Steroid Sparing Agent for Uveitis Patients
|
Phase 2/Phase 3 | |
Completed |
NCT04183387 -
Simvastatin in Uveitis
|
Phase 2 | |
Completed |
NCT01983488 -
Clinical Outcome in Uveitis
|
||
Withdrawn |
NCT00499551 -
A Phase I/IIa Study for the Treatment of Uveitis With Iontophoresis
|
Phase 1/Phase 2 | |
Completed |
NCT00132691 -
Multicenter Uveitis Steroid Treatment (MUST) Trial
|
Phase 4 | |
Terminated |
NCT00114062 -
Study to Treat Uveitis Associated Macular Edema
|
Phase 2 | |
Completed |
NCT00476593 -
Retinal OCT and (mfERG) Related to Age, Sex, and the Use of Anti-inflammatory Medications
|
N/A | |
Completed |
NCT00001867 -
Effect of Pregnancy on Uveitis
|
N/A | |
Completed |
NCT00379275 -
Eye and Immunogenetic Features of Sarcoidosis
|
N/A | |
Active, not recruiting |
NCT03828019 -
Adalimumab vs. Conventional Immunosuppression for Uveitis Trial
|
Phase 3 | |
Terminated |
NCT01939691 -
Macular Edema Nepafenac vs. Difluprednate Uveitis Trial
|
Phase 4 | |
Active, not recruiting |
NCT03889860 -
Objective Choroidal Thickness Measurements in Uveitis
|
||
Completed |
NCT00070759 -
Daclizumab to Treat Non-Infectious Sight-Threatening Uveitis
|
Phase 2 | |
Recruiting |
NCT05486468 -
The Use of Two YUTIQ Versus Sham for Treatment of Chronic Non Infectious Intraocular Inflammation Affecting the Posterior Segment
|
Phase 3 | |
Active, not recruiting |
NCT05385757 -
UNICORNS: Uveitis in Childhood Prospective National Cohort Study
|